Clinical Trials Logo

Renal Insufficiency clinical trials

View clinical trials related to Renal Insufficiency.

Filter by:

NCT ID: NCT01533545 Terminated - Clinical trials for Renal Insufficiency, Chronic

Effect of Epinephrine on Systemic Absorption of Mepivacaine in Uremic Patients

Start date: September 2012
Phase: N/A
Study type: Interventional

The aim of this study is to determine the effect of epinephrine on systemic absorption of local anaesthetic mepivacaine administered for brachial plexus block in uremic patients scheduled for creation or repair of an arteriovenous fistula. Furthermore, an impact of epinephrine on the central circulation and peripheral tissue oxygenation will be evaluated.

NCT ID: NCT01529658 Active, not recruiting - Cancer Clinical Trials

Renal Hypothermia During Partial Nephrectomy

Start date: September 2012
Phase: N/A
Study type: Interventional

The Objective is to determine if renal hypothermia during open partial nephrectomy results in improved post-operative renal function compared to warm ischemia. Primary Aim is to determine the effect of hypothermia on preservation of overall renal function compared to no hypothermia in patients who require hilar vessel clamping during open partial nephrectomy for a renal tumor. Hypothesis: Hypothermia will result in improved post-operative preservation of overall renal function. Secondary Aim is to determine the effect of hypothermia on preservation of affected renal function (kidney with the tumor) compared to no hypothermia in patients who require hilar vessel clamping during open partial nephrectomy for a renal tumor. Hypothesis: Hypothermia will result in improved post-operative preservation of affected renal function.

NCT ID: NCT01526746 Completed - Renal Impairment Clinical Trials

Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function

Start date: February 2012
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to understand whether there is any difference in the amount of tasimelteon (including its breakdown products) in the blood of individuals with severe renal impairment compared to individuals who have normal renal function. The safety and tolerability of tasimelteon will also be assessed throughout this study.

NCT ID: NCT01524276 Recruiting - Clinical trials for Coronary Artery Disease

Product Surveillance Registry

PSR
Start date: January 2012
Phase:
Study type: Observational

The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.

NCT ID: NCT01522313 Completed - Acute Kidney Injury Clinical Trials

Influence of Perioperative Kidney Function on Postoperative Outcome

NEPHRANEST
Start date: January 2006
Phase: N/A
Study type: Observational

This study investigates the influence of perioperative changes in serum creatinine on hospital length of stay and mortality.

NCT ID: NCT01515878 Recruiting - Clinical trials for Cardiovascular Diseases

Hemocontrol's Effectiveness on the Reduction of Cardiovascular Long-term EventS

HERACLES
Start date: February 2012
Phase: Phase 4
Study type: Interventional

It is hypothesized that a consistent use of the Hemocontrol TM biofeedback function improves long-term cardiovascular outcome, mediated by reduced hypertension due to fluid overload and by reduced incidence of intradialytic hypotensive episodes

NCT ID: NCT01512849 Completed - Clinical trials for Type 2 Diabetes Mellitus

A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

Start date: January 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the PK/PD and safety of TA-7284 in patients with type 2 diabetes mellitus who have moderate renal impairment.

NCT ID: NCT01512667 Completed - Renal Insufficiency Clinical Trials

Pharmacokinetic Assessment of Single-Dose Odanacatib (MK-0822) in Subjects With Severe Renal Insufficiency (MK-0822-067)

Start date: January 17, 2012
Phase: Phase 1
Study type: Interventional

This study will investigate and compare pharmacokinetics of a single 50 mg dose of odanacatib administered to participants with impaired renal/kidney function to those of a healthy matched control group. The primary hypothesis is that plasma AUC0-∞ of odanacatib in participants with impaired renal function is similar to that in matched healthy participants following a single 50 mg oral dose.

NCT ID: NCT01510899 Completed - Healthy Volunteer Clinical Trials

A Study on the Effect of Renal Impairment on the Pharmacokinetics of RO4917838

Start date: October 2011
Phase: Phase 1
Study type: Interventional

This open-label, single-dose, parallel-group study will investigate the pharmacokinetics and safety of RO4917838 in healthy and renal impaired subjects. Subjects will receive a single dose of RO4917838.

NCT ID: NCT01510795 Enrolling by invitation - Clinical trials for Kidney Failure, Chronic

Mineralocorticoid Receptor Antagonist and Kidney Allograft Histology

Start date: January 2012
Phase: Phase 4
Study type: Interventional

Chronic allograft nephropathy is one of dominant causes of long term kidney transplant failure. Its main histological determinant is interstitial fibrosis and tubular atrophy. Mechanisms of these changes are multifactorial and are not completely elucidated. Epithelial mesenchymal transition (EMT) might be one of the mechanisms. On molecular level role of renin angiotensin aldosterone system (RAAS) has been recognized. Recently, mineralocorticoid hormone aldosterone has been proposed as a possible direct contributor to the progression of renal injury and fibrosis, beside his well known role as a regulator of extracellular fluid volume and sodium and potassium balance. In this study the investigators will determine the impact of mineralocorticoid receptor antagonist use on progression of chronic scores in transplanted kidney over one year. The investigators hypothesis is that spironolactone use in kidney transplant patients will slow down progression of chronic histological changes- interstitial fibrosis, tubular atrophy and arteriolar hyalinosis.